Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITDAEPS (Basic)EPS (Weighted Average and Diluted)Income towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Summit Therapeutics (SMMT) EPS (Basic) (2022 - 2025)

Summit Therapeutics' EPS (Basic) history spans 4 years, with the latest figure at -$0.28 for Q4 2025.

  • For Q4 2025, EPS (Basic) fell 211.11% year-over-year to -$0.28; the TTM value through Dec 2025 reached -$1.44, down 350.0%, while the annual FY2025 figure was -$1.44, 364.52% down from the prior year.
  • EPS (Basic) reached -$0.28 in Q4 2025 per SMMT's latest filing, up from -$0.31 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of -$0.01 in Q4 2023 to a low of -$1.43 in Q1 2023.
  • Average EPS (Basic) over 4 years is -$0.24, with a median of -$0.09 recorded in 2024.
  • The largest YoY upside for EPS (Basic) was 95.8% in 2024 against a maximum downside of 800.0% in 2024.
  • A 4-year view of EPS (Basic) shows it stood at -$0.04 in 2022, then skyrocketed by 75.0% to -$0.01 in 2023, then crashed by 800.0% to -$0.09 in 2024, then tumbled by 211.11% to -$0.28 in 2025.
  • Per Business Quant, the three most recent readings for SMMT's EPS (Basic) are -$0.28 (Q4 2025), -$0.31 (Q3 2025), and -$0.76 (Q2 2025).